Investor Presentaiton
Key Product Pipeline - USA
23
Para IVs in the pipeline
>>> 15
Approved (either tentative or fully)
Key Solo FTFs (Para IV) in the pipeline
Key Para IV products in the pipeline
Therapeutic
Key Brand
Molecule
Key Brand
Molecule
Segment Primary Indication
Tracleer
Kyprolis
Bosentan (32mg)
Anti-hypertensive
Eliquis
Apixaban
Therapeutic
Segment Primary Indication
Anticogulant
Carfilzomib (10mg)
Cancer/Multiple Myeloma
Ozempic
Semaglutide pen
Diabetes
Imbruvica
Ibrutinib (tablet)
Cancer/Leukaemia
Zydelig
Idelalisib
Cancer
Pomalyst
Pomalidomide
Lynparza
Olaparib
Ovarian/Breast Cancer
Lonsurf
Ozempic
Semaglutide pen (8mg/3ml)
Diabetes
Trifluridine/Tipracil
Yondelis
Trabectedin
Balversa
Erdafitinib
Bladder Cancer
Wegovy
Semaglutide
Weight Loss
Calquence
Acalabrutinib
Cancer/Multiple Myeloma
Metastatic colorectal cancer
Advanced soft-tissue sarcoma/
ovarian cancer
Cancer/Blood
Note: Data as of Dec 31, 2023
Natco Pharma Limited - Earnings Presentation - Q3FY24
10View entire presentation